[Comparative study of a new antihistamine, mequitazine, and placebos].
In a double-blind trial lasting 2 weeks, a new, long-acting antihistamine, Mequitazine, and a placebo, were compared. 115 allergic patients participated in this experiment (mequitazine n = 56, placebo n = 59). Therapeutic results and the effect on diurnal alertness were evaluated by means of a questionnaire filled in daily by the patients. Whether considering the day by day results or the results of the entire treatment period, statistically, Mequitazine (10 mg/24 hrs) is very significantly more active than the placebo. The daytime drowsiness induced by Mequitazine is statistically no greater than that induced by the placebo, whether analyzed on a day by day basis or over the entire treatment period (P = 0.23). The side effects, 8 for Mequitazine, 5 for placebo, are mild and did not lead to discontinuation of the treatment in the Mequitazine group.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D005260:Female; D006634:Histamine H1 Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010640:Phenothiazines / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D011812:Quinuclidines / Q000009:adverse effects / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D013997:Time Factors
D006634:Histamine H1 Antagonists; D010640:Phenothiazines; D010919:Placebos; D011812:Quinuclidines
Essai comparé d'un nouvel antihistaminique, la méquitazine, et d'un placebo